Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Taiwan Biotech Co., Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Taiwan Biotech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01615913
First received: June 4, 2012
Last updated: June 6, 2012
Last verified: June 2012

June 4, 2012
June 6, 2012
April 2012
June 2013   (final data collection date for primary outcome measure)
Presented by pharmacokinetic data (drug plasma concentrations vs. time) or drug deposit amounts in feet nails. [ Time Frame: baseline, 8-week, 16-week and 24-week ] [ Designated as safety issue: Yes ]
Both terbinafine and ketoconazole plasma concentration, and their residual contents in toenails will be measured with a validated LC/MS‐MS method.
Same as current
Complete list of historical versions of study NCT01615913 on ClinicalTrials.gov Archive Site
  • (1) Efficacy is evaluated 24 weeks after the start of treatment and will be recorded at baseline, 8-week, 16-week and 24-week. [ Time Frame: baseline, 8-week, 16-week and 24-week ] [ Designated as safety issue: Yes ]

    The degrees of improvement are assessed based on each toenail as follows:

    1. Complete cure is defined as regeneration of a healthy nail plate to replace the diseased nail.
    2. Marked improvement is defined as regeneration of a healthy nail plate in at least 70% of the affected nail.
    3. Improvement is defined as regeneration in 40-70% of the affected nail.
    4. Slight improvement is defined as regeneration in less than 40%.
    5. No change is defined as the absence of change or exacerbation of the disease condition or the side effect.
  • (2) Safety Monitoring [ Time Frame: baseline, 8-week, 16-week and 24-week ] [ Designated as safety issue: Yes ]
    Adverse events, both local and systemic, will be recorded and their relation to the trial drugs is judged.
Same as current
Not Provided
Not Provided
 
Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole
Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine and Ketoconazole Formulation

This study is to explore the optimization of anti‐onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3‐mg, 6‐mg and 8‐mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2‐mg ketoconazole/patch) and its safety profile.

This study is to explore the optimization of anti‐onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3‐mg, 6‐mg and 8‐mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2‐mg ketoconazole/patch) and its safety profile. At least 18 patients (age: 20 to 75 years old) with one or two feet toenails infected simultaneously need to complete the whole study. Patients will be assigned to one of patch groups. The patients with only one infected toenail will also apply one patch on other foot with uninfected toenail. The patch will be applied on the foot on the dorsal site and leave it there for two consecutive days. Totally six patches will be used for each week. The duration of therapy will be 24 weeks. The patients' blood sample and toenail clippings will be collected every 8 weeks and will be analyzed as well as the safety profiles. The most appropriate patch formulation will be selected on the drug content residues in toenail. The safety profile will be also presented and discussed with various anti‐onychomycosis patch formulations.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Onychomycosis
  • Drug: 3 mg terbinafine and 2 mg ketoconazole containing patch
    A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
  • Drug: 6 mg terbinafine and 2 mg ketoconazole containing patch
    A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
  • Drug: 8 mg terbinafine and 2 mg ketoconazole containing patch
    A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
  • Experimental: 3% terbinafine patch
    A 10‐cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
    Intervention: Drug: 3 mg terbinafine and 2 mg ketoconazole containing patch
  • Experimental: 6% terbinafine patch
    A 10‐cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
    Intervention: Drug: 6 mg terbinafine and 2 mg ketoconazole containing patch
  • Experimental: 8% terbinafine patch
    A 10‐cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
    Intervention: Drug: 8 mg terbinafine and 2 mg ketoconazole containing patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and females 20‐75 years of age
  • Fungal infection of one or both toenails will be confirmed using the method of histopathological examination with periodic acid‐Schiff (PAS) staining (Yang JH, et al., 2007)
  • The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non‐dermatophyte)
  • The target toenail area must have at least 25% to no more than 75% disease involvement without spikes
  • Patients agree to sign the informed consent form

Exclusion Criteria:

  • Using any kind of systemic or topical nail lacquer solution antifungal drugs within 6 months before at screening visit; or using any other topical antifungal agents, such as ointment, cream, gel, solution, suspension, oil or lotion forms, within two weeks before at screening visits
  • Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold
  • Presence of dermatophytoma on the target nail
  • Using professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Patients who are unwilling to provide nail clippings
  • Patients who have been previously reported to be allergic to topical or systemic terbinafine or ketoconazole therapy or both
  • Known pregnancy or plan to get pregnant within study duration or lactation at time of enrollment
  • Unconsciousness or inability to understand this form or this study project.
Both
25 Years to 75 Years
No
Contact: Mei-Fang Wen 886-2-2737-2181 ext 3925 985146@h.tmu.edu.tw
Taiwan
 
NCT01615913
TE9512
Yes
Taiwan Biotech Co., Ltd.
Taiwan Biotech Co., Ltd.
Not Provided
Not Provided
Taiwan Biotech Co., Ltd.
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP